June 19 - 22, 2018
Hyatt Regency Montreal
Montreal, QC, Canada
Abstract submission deadline: Monday, March 12
Advance registration deadline: Thursday, May 3
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 19.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Friday, August 3. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the AACR website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
REQUEST FOR CREDIT SURVEY
Metastatic cancer is generally incurable. Novel therapies may prolong life or even induce stable disease in metastatic patients. Since the majority of cancer patients in Western countries are diagnosed with early stage cancer (i.e., without evidence of manifestation of distant metastasis), there is apparently a great chance to cure the disease when tumor load is minimal. However, to date there are no therapies that target DTCs at the single-cell level or at the level of micrometastases (before detection by conventional imaging). The reason is that our understanding of what happens from the time a tumor cell disseminates from a primary tumor to the time it manifests as a metastatic lesion is lacking. Little research has been performed to understand the specific rules and mechanisms of minimal residual disease, including clonal evolution at the metastatic site, epigenetic programs, interaction with organ defense and immune systems, mechanisms of dormancy and reawakening, and last but not least, mechanisms of therapy resistance in specific niches. A measurable output from this venture will be therapeutic approaches to target and eradicate DTCs before they develop into deadly metastases. There is an educational need to create awareness in the basic, translational, and clinical research communities of how little we understand about the biology of minimal residual disease in solid and liquid cancers. There is a need to communicate new findings and bring together fields that may be already generating important information that could be applied to target dormant residual cancer and prevent recurrences. A measurable output from this venture will be therapeutic approaches to target and eradicate DTCs before they develop into deadly metastases.
This conference will be of interest to physicians, cancer biologists, PhDs, and MSc trainees in cell biology, cancer biology, and bioengineering at managing recurrences in both solid and liquid tumors. After participating in this CME activity, physicians should be able to:
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by Professional Educational Grants and will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or email@example.com.